Core Viewpoint - Pacira BioSciences, Inc. is set to report its first quarter financial results on May 8, 2025, and will host a live conference call following the release [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3] - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Insights - Pacira BioSciences, Inc. announced new data on its gene therapy candidate PCRX-201, showing sustained improvements in knee pain, stiffness, and function for up to two years after a single local administration in patients with varying severity of osteoarthritis [2][3][9] Study Findings - The study presented at the 2025 OARSI World Congress demonstrated that PCRX-201 provided clinically meaningful improvements across all structural severity subgroups, including advanced disease [1][2] - The open-label, phase 1 trial involved 72 patients aged 30 to 80, stratified by the severity of knee osteoarthritis, graded on the Kellgren-Lawrence scale [4] - Improvements in pain, stiffness, and function were assessed using the WOMAC and KOOS scores, showing significant reductions across all cohorts and severity levels [6][7] Treatment Efficacy - Patients receiving corticosteroid pretreatment experienced greater benefits, with pain reductions of 48%-65% and stiffness reductions of 53%-72%, compared to 41%-58% and 33%-53% in the non-pretreated cohort [7] - The greatest improvement was observed in patients with K/L grade 2 osteoarthritis [7] Safety Profile - No serious treatment-emergent adverse events were reported, with treatment-related joint effusions being the most common adverse event, occurring in 36% of the corticosteroid-pretreated group and 61% of the non-pretreated group [8] Regulatory Designations - PCRX-201 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in March 2024, facilitating efficient drug development and potential accelerated approval [9][10] - The therapy also received Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency in May 2023 [10][13] Future Developments - Following promising Phase 1 results, a Phase 2 study (ASCEND study) is underway for PCRX-201, focusing on the treatment of knee osteoarthritis [11][13] - The company aims to advance its position as an innovative biopharmaceutical entity through this development [9]

Summary of Pacira BioSciences Inc (PCRX) Update / Briefing April 27, 2025 Company Overview - **Company**: Pacira BioSciences Inc (PCRX) - **Focus**: Development of innovative therapies for pain management and degenerative diseases, specifically targeting osteoarthritis Key Points - **Commitment to Change**: The company emphasizes its dedication to creating lasting improvements for patients suffering from pain and degenerative diseases like osteoarthritis [1] - **Clinical Development Plan**: Introduction of PCRX201, an innovative gene therapy aimed at addressing both the underlying causes and symptoms of knee osteoarthritis [1] Additional Important Content - **Target Patient Population**: The focus on osteoarthritis indicates a strategic alignment with a significant patient demographic that experiences chronic pain [1]

PCRX-201 Overview - PCRX-201 is an innovative, locally-administered gene therapy targeting the underlying cause of osteoarthritis (OA)[1, 10] - It offers unprecedented pain relief and durability for at least 2 years from a single injection across all levels of disease severity[11] - Phase 1 trial data showed a 48-65% reduction from baseline pain through 104 weeks[13] - In the Phase 1 trial, over 70% of patients experienced a greater than 50% improvement in pain and stiffness vs baseline at week 16 and 78[15] Clinical Development Plan - The company plans a clinical development pathway including Phase 2 Part A, Phase 2 Part B, Phase 2 Bilateral Dosing, Phase 3 Single Injection, and Phase 3 Extension with repeat dosing, targeting a BLA submission by 2032[17, 19] Phase 2 Study Design - The Phase 2 study is a two-part, randomized, double-blind, active-controlled study to assess the safety and tolerability of PCRX-201 in subjects with painful knee OA[20, 22] - Part A will use existing inventory from the Phase 1 trial, while Part B will use a new manufacturing process intended for commercial scale-up[28] - Both parts will pretreat all subjects with a 40 mg intra-articular (IA) dose of methylprednisolone acetate[28, 40, 43] - Part A plans for a maximum of 45 subjects (15 per group), and Part B plans for 90 subjects (30 per group)[32, 39, 42]

Core Insights - Pacira BioSciences, Inc. is presenting new 104-week data for its gene therapy candidate PCRX-201 at the OARSI World Congress, highlighting its commitment to innovative, non-opioid pain therapies [1][4]. Group 1: Product Information - PCRX-201 (enekinragene inzadenovec) is based on a proprietary high-capacity adenovirus vector platform and targets chronic inflammatory processes in knee osteoarthritis, affecting over 14 million individuals in the U.S. [3] - The therapy has shown sustained improvements in knee pain, stiffness, and function for up to two years post-administration, with a favorable safety profile [4]. - PCRX-201 has received RMAT designation from the FDA and ATMP designation from the EMA, marking it as the first gene therapy to achieve such regulatory recognition in knee osteoarthritis [4]. Group 2: Clinical Development - Following promising Phase 1 results, a Phase 2 study (ASCEND study) is currently underway for PCRX-201 to further evaluate its efficacy in treating knee osteoarthritis [5]. Group 3: Company Overview - Pacira specializes in non-opioid pain therapies and has three commercial-stage products: EXPAREL®, ZILRETTA®, and iovera® [6]. - The company is advancing the development of PCRX-201 as a novel treatment option for prevalent diseases like osteoarthritis [6].

Group 1 - PharmaCorp Rx Inc. has filed its audited financial statements and associated MD&A for the year ended December 31, 2024, on SEDAR+ [1] - The company operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available [2] - PharmaCorp intends to acquire independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2] Group 2 - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [2]

Core Insights - Pacira (PCRX) has consistently surpassed earnings estimates, averaging a 7.77% beat over the last two quarters [1] - In the last reported quarter, Pacira achieved earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.86 per share by 5.81% [2] - The previous quarter also saw Pacira outperforming expectations, with actual earnings of $0.79 per share against an estimate of $0.72 per share, resulting in a surprise of 9.72% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Pacira, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [4] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [5] - Pacira currently has an Earnings ESP of +12.06%, suggesting analysts are optimistic about the company's earnings prospects [7] Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [6] - A positive Earnings ESP combined with a Zacks Rank 3 indicates a potential earnings beat, while a negative value reduces predictive power but does not guarantee a miss [7] - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [8]

Core Viewpoint - DOMA Perpetual believes that Pacira BioSciences' stock is undervalued, presenting an opportunity for the company to execute its largest buyback in history [1][4]. Group 1: Capital Allocation and Shareholder Value - DOMA Perpetual views the new capital allocation announcement as a strong commitment from Pacira's Board to enhance shareholder value [2]. - The combination of a $300 million share repurchase program and a focus on increasing pre-tax net income margins is expected to strengthen shareholder returns [3]. - The management is now tasked with effectively executing these initiatives to realize their potential [3]. Group 2: Growth and Financial Position - DOMA Perpetual is encouraged by Pacira's steps towards long-term value creation, indicating a period of rapid growth for the company [4]. - The new capital allocation priorities reflect Pacira's considerable momentum in scaling earnings and free cash flow, allowing for meaningful capital returns to shareholders while still investing in growth [4]. - The stock is considered undervalued relative to its historical average and the anticipated multi-year growth cycle ahead [4].

Core Viewpoint - Pacira BioSciences, Inc. is committed to enhancing shareholder value through strategic actions aimed at optimizing operational performance and creating sustainable, long-term value for shareholders [1][3] Group 1: Strategic Initiatives - The company has made significant progress in advancing its 5x30 strategy to transition into an innovative biopharmaceutical organization and aims to become a leader in musculoskeletal pain and related areas by 2030 [2] - The Board of Directors has authorized a share repurchase program of up to $300 million, reinforcing confidence in the company's growth strategy and commitment to shareholder value [5] - The company is focused on enhancing operational efficiency and aims to improve gross margins by 5 percentage points over 2024 [5] Group 2: Product Portfolio - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º, which are designed to manage pain without opioids [4] - The company is advancing the development of PCRX-201, a novel locally administered gene therapy aimed at treating prevalent diseases like osteoarthritis [4] Group 3: Future Outlook - Pacira plans to treat more than 3 million patients annually and aims for a double-digit compounded annual growth rate for revenue [5] - The company is expanding its clinical pipeline with five novel programs in development and establishing five new partnerships, including pipeline and commercial agreements [5]

Core Insights - Pacira BioSciences, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on non-opioid pain management therapies, with key products including Exparel, Zilretta, and iovera [1] Group 1 - The NOPAIN Act is expected to provide a favorable secular tailwind for Pacira BioSciences, enhancing the market for non-opioid pain management solutions [1]